The Effect of Cannabidiol on Nociceptive Behaviour and the Endocannabinoid System in an Incisional Wound Model
<b>Background/Objectives:</b> Wound-related pain is a common, yet inadequately managed condition, and new therapeutic strategies are warranted. Limited data suggests that phytocannabinoids and cannabis may alleviate wound-related pain; however, further studies are required. This study investigated the effects of systemic administration of cannabidiol (CBD) on nociceptive behaviour following dorsum incision and on the endocannabinoid system. <b>Methods</b>: Male Sprague-Dawley rats (150-200 g on arrival, <i>n</i> = 9/group) underwent a 1.2 cm incision on the hairy skin of the dorsum or sham procedure. Back and hind paw mechanical withdrawal thresholds were assessed at baseline and post-surgery/sham days (PSDs) 1, 4, 7, and 8 using manual and electronic von Frey tests, respectively. On PSD 8, the effect of a single acute administration of CBD (3, 10, or 30 mg/kg, i.p.) on mechanical hypersensitivity in the dorsum and hind paws was assessed. The levels of endocannabinoids and <i>N</i>-acylethanolamines in the plasma and discrete brain regions following CBD administration were analysed. <b>Results</b>: Robust mechanical hypersensitivity was evident in the dorsum and hind paws following the incision. CBD (3 mg/kg) partially attenuated primary mechanical hypersensitivity in the dorsum, in a site- and dose-specific manner. CBD had no effect on secondary mechanical hypersensitivity. CBD did not alter the levels of endocannabinoids or <i>N</i>-acylethanolamines, but in rats that received CBD (3 mg/kg), levels of 2-AG were lower in the contralateral amygdala and levels of AEA were higher in the contralateral lumbar spinal cord, compared to the ipsilateral sides. <b>Conclusions</b>: These data provide evidence for antinociceptive effects of CBD in a model of incisional wound-related pain. Further research on CBD's mechanism(s) of action is warranted. The potential antinociceptive effects of other phytocannabinoids in this model should also be investigated.
Authors
- Catherine Healy (ORCID: https://orcid.org/0000-0003-1072-6801)
- Georgina Gethin (ORCID: https://orcid.org/0000-0001-5859-8357)
- Abhay Pandit (ORCID: https://orcid.org/0000-0002-6292-4933)
- David P. Finn (ORCID: https://orcid.org/0000-0001-6186-621X)
- Mark Redmond (ORCID: https://orcid.org/0000-0002-7629-3538)
- Rosmara Infantino (ORCID: https://orcid.org/0000-0003-1266-6881)
- Mary A. Hopkins (ORCID: https://orcid.org/0000-0001-9797-3850)
Institutions
- Science Foundation Ireland (IE)
- Ollscoil na Gaillimhe – University of Galway (IE)
- University Hospital Galway (IE)
- COPE Galway (IE)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2025-12-24
- DOI
- https://doi.org/10.3390/ph19010043
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Galway